The licensing deals will bolster Takeda’s ADC portfolio, which the company now considers a key modality focus within its ...

Early-stage equity raises for biotechs surged by 71% in Q3 2025, hinting that the funding freeze that has gripped the ...

Ipsen is set to purchase all issued and outstanding shares of the French biotech company ImCheck Therapeutics.

Remote monitoring technologies offer a vital option for people with diabetes to manage their conditions, with tech developed ...

Alkermes has agreed to acquire Avadel Pharmaceuticals for up to $20 per share in cash, valuing Avadel at $2.1bn. The ...

ICH gives CGT developers a regulatory framework that finally matches the speed and flexibility their groundbreaking therapies ...

HPAPI manufacturing requires the highest safety and containment standards. With geopolitical tensions threatening critical ...

Nearly two dozen antibody drug conjugates (ADCs) have now been approved worldwide and revenues were already well into the ...

The latest in a trend of companies stepping back from cell and gene therapies amid regulatory uncertainty and manufacturing ...

The potential of moving the combination to the earlier MIBC setting significantly increases the Padcev market.

Ventus has entered a multi-year partnership with Roche’s Genentech for the discovery and optimisation of new small-molecule medicines ...

The results strengthen Jiangsu Hengrui’s dominance in the Chinese HCC market, showing potential for camrelizumab and ...